Internal Medicine, Hematology & Oncology · Memphis, TN
NPI
1770581662
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
6
Medicare group memberships
Hospitals
5
Hospital affiliations
6029 Walnut Grove Rd, Suite #301
Memphis, TN, 38120
Phone (901) 747-9081
Groups this clinician bills Medicare through
Medicare paid, 2024
$138K
2,391 services
Medicare patients, 2024
667
Average age 75
Drug cost, 2024
$6.6M
2,181 prescriptions
Company payments, 2025
$19K
From 46 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Donald S Gravenor was code 99214 (office e&m - established), 736 times for 303 patients. In total Donald S Gravenor billed 2,391 services in 28 codes, and Medicare paid $138K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-06-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 736 | 303 | $62.77 | $46K |
| 99214 Office E&M - Established | Office | 337 | 177 | $66.75 | $22K |
| 99232 Hospital E&M - Subsequent | Facility | 301 | 111 | $55.41 | $17K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 284 | 136 | $11.61 | $3,298 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 178 | 105 | $10.22 | $1,818 |
| 99233 Hospital E&M - Subsequent | Facility | 108 | 73 | $85.52 | $9,236 |
| 99215 Office E&M - Established | Facility | 79 | 57 | $97.83 | $7,729 |
| 99204 Office E&M - New | Facility | 71 | 71 | $86.98 | $6,175 |
| 99223 Hospital E&M - Initial | Facility | 66 | 57 | $121.43 | $8,015 |
| 99204 Office E&M - New | Office | 37 | 37 | $84.85 | $3,140 |
| 99215 Office E&M - Established | Office | 30 | 24 | $103.04 | $3,091 |
| 99213 Office E&M - Established | Office | 29 | 27 | $33.34 | $967 |
| 99205 Office E&M - New | Office | 19 | 19 | $130.95 | $2,488 |
| 99205 Office E&M - New | Facility | 18 | 18 | $125.59 | $2,261 |
| 99213 Office E&M - Established | Facility | 16 | 16 | $40.25 | $644 |
By year: 2022 $142K for 1,969 services; 2023 $141K for 2,094 services; 2024 $138K for 2,391 services.
Medicare prescription drug claims, 2024
In 2024, the drug Donald S Gravenor prescribed most often to Medicare patients was Letrozole, with 256 prescriptions and refills. In total Donald S Gravenor wrote 2,181 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 256 | 477 | 52 | $3,785 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 119 | 119 | 38 | $2,614 |
| Acyclovir Generic | 79 | 125 | 15 | $1,130 |
| Ondansetron Odt Ondansetron | 73 | 73 | 42 | $1,297 |
| Lenalidomide Generic | 73 | 73 | Under 11 | $968K |
| Eliquis Apixaban | 72 | 108 | 19 | $60K |
| Diazepam Generic | 69 | 69 | Under 11 | $306 |
| Potassium Chloride Generic | 69 | 117 | 32 | $1,688 |
| Ninlaro Ixazomib Citrate | 68 | 68 | Under 11 | $863K |
| Gabapentin Generic | 62 | 76 | 16 | $316 |
| Xarelto Rivaroxaban | 56 | 98 | 14 | $54K |
| Anastrozole Generic | 40 | 92 | 14 | $546 |
| Prochlorperazine Maleate Generic | 39 | 39 | 23 | $571 |
| Pantoprazole Sodium Generic | 38 | 84 | 15 | $290 |
| Morphine Sulfate Er Morphine Sulfate | 37 | 37 | Under 11 | $2,671 |
Brand drugs: 554 claims; generic drugs: 1,627 claims; opioid claims: 260.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Donald S Gravenor $19K ($19K in general payments such as food, travel and fees) from 46 companies. The largest payer was Janssen Biotech, Inc. with $14K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 19 | $14K |
| Daiichi Sankyo Inc. 4568.T | 12 | $917 |
| Pfizer Inc. PFE | 18 | $341 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $293 |
| E.R. Squibb & Sons, L.L.C. BMY | 20 | $292 |
| Gilead Sciences, Inc. GILD | 9 | $273 |
| Lilly USA, LLC LLY | 9 | $251 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 9 | $238 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $232 |
| Abbvie Inc. ABBV | 11 | $207 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.